← Back to all trials
Not Yet Recruiting
NCT05750589
Sterilizing Eye Solution to Improve Patient Comfort
Conditions: Retinal Disease
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: 1
Phase: PHASE3
Enrollment: 240
Sponsor: iRenix Medical, Inc.
Summary
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
Eligibility Criteria
Inclusion Criteria:Capable of giving informed consentStated willingness to comply with all study procedures and availability for the duration of the studyMale or female, ≥ 18 years of age and receiving intravitreal anti-VEGF injections in one or both eyesExclusion Criteria:Current or past diagnosis of endophthalmitisCurrent diagnosis of uveitisMonocular patients (vision 20/100 or worse in one eye) who are receiving injections in the better seeing eyeCurrent use of viscous lidocaine products for ocular anesthesia prior to IVTCurrently receiving intravitreal steroid injectionsConcurrent participation in another clinical trialFemales who are pregnant, planning to become pregnant or lactating
Source: ClinicalTrials.gov (NCT05750589). StuddyBuddy aggregates publicly available trial information.